ArticleCancer medicine2026
Infection Profiles Under Venetoclax-Based Therapy in Newly Diagnosed Acute Myeloid Leukemia: A Real-World Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Venetoclax (VEN)-based regimens improve remission in acute myeloid leukemia (AML), but infectious toxicity remains a concern. We compared infection profiles under VEN-based versus conventional therapy in newly diagnosed, non-M3 AML at a single tertiary center (2015-2024; n = 358; VEN = 156; non-VEN = 202). After 1:1 propensity-score matching on nine baseline covariates (115 per group), we assessed infection rates and event density (events per 1000 person-days) by site and pathogen, time to first infection (120-day cumulative incidence), and landmark associations between early infections and progression-free survival (PFS). Baseline predictors of microbiologically documented infection (MDI) were modeled in the pre-matching cohort. VEN was associated with higher febrile-neutropenia (FN) event density (IRR, 1.77; 95% CI, 1.33-2.36; p < 0.001; 16.40 vs. 9.27 per 1000 person-days). Site-level patterns diverged: upper-respiratory and lung infections showed lower first-event incidence with VEN, whereas skin/soft-tissue and perianal sites showed higher event density without higher patient-level incidence. By pathogen, bacterial and fungal first events were fewer with VEN while event densities were comparable; viral infections occurred earlier and accrued higher cumulative incidence. Cumulatively, the first infection was lower with VEN at days 30, 60, and 90 but converged by day 120. In the pre-matching cohort, higher HCT-CI (1-2/≥ 3 vs. 0) and higher DBIL independently predicted MDI, while female sex predicted lower risk. MDIs within 90 days-bacterial/fungal-driven-were associated with inferior PFS at 100 and 365 days, whereas early viral infections showed no association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.